• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.91
  • VXN 16.64
  • VXO 14.31
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

ENZ (Enzo Biochem Inc. ($0.01 Par Value))
Last Trade 2.63 Dividend/Share 0 PE Ratio null
Date March 20-2019 Dividend Yield 0.000 Return on Assets -23.47
Change 0.03 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.21 Price/Sale 1.331
Ask 0 LatestEPS Date 2018-07-31 Price to Book 1.78
Volume 6104 EPS ttm 0.000 Institutional % 86.4
Avg Volume 0.19M Shares Outstanding 47.24M Insider % 12
Open 2.6 Float 41.56M Short Ratio 4.710
Prev Close 2.6 Return On Equity -29.81 5 Year Change % -0.395
High 2.65 Consensus EPS 0 2 Year Change % -0.627
Low 2.57 No. of Estimate 0.000 1 Year Change % -0.586
52 Week High 6.8904 EPS Surprise $ null YTD Change % -0.061
52 Week Low 2.32 EPS Surprise Percent 0 6 Month Change % -0.437
52 Week Change -59.690 EBITDA 0M 3 Month Change % -0.077
50 Day MA 3.4038 Revenue 0M 1 Month Change % -0.251
200 Day MA Gross Profit 0M 5 Day Change % -0.011
Market Cap 122.83M Cash 0M 30 Day Change % -0.327
Beta 1.288229 Debt 0M Stock Exchange New York Stock Exchange
Sector Healthcare Revenue Per Share 0 Short Interest 814514
Short Date 2019-02-28 Revenue Per Employee 0 Short Ratio 4.710
Data courtesy of IEX
Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.